MDM2 T309G polymorphism and esophageal cancer risk: a meta-analysis

Caipeng Lei; Weiguo Zhang; Junli Fan; Bin Qiao; Qiang Chen; Qin Liu; Chunling Zhao

MDM2 T309G polymorphism and esophageal cancer risk: a meta-analysis

Int J Clin Exp Med. 2015 Aug 15;8(8):13413-6. eCollection 2015.

Authors

Caipeng Lei¹, Weiguo Zhang¹, Junli Fan¹, Bin Qiao¹, Qiang Chen¹, Qin Liu¹, Chunling Zhao²

Affiliations

¹ Department of Oncology Surgery, The First Affiliated Hospital of Henan University of Science and Tecnology Luoyang 471003, Henan, China.
² Department of Oncology, The First Affiliated Hospital of Henan University of Science and Tecnology Luoyang 471003, Henan, China.

PMID: 26550276
PMCID: PMC4612961

Abstract

Murine double minute 2 (MDM2) has suggested to play an important role in esophageal cancer. The association between MDM2 T309G polymorphism and esophageal cancer risk was inconclusive. To clarify the possible association, we conducted a meta-analysis. We searched in the PubMed, Embase, and Wanfang databases. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to assess the strength of association. A total of 6 studies with 4909 cases and controls were included based on the search criteria. The MDM2 T309G polymorphism was associated with a significantly decreased risk of esophageal cancer (OR=0.88; 95% CI, 0.81-0.96; I(2)=22%). When stratified by type of race, a significantly decreased esophageal cancer risk were observed in Asians (OR=0.85; 95% CI, 0.78-0.93; I(2)=0%). In conclusion, this meta-analysis suggested that MDM2 T309G polymorphism was associated with a significantly decreased risk of esophageal cancer.

Keywords: Esophageal cancer; MDM2; meta-analysis; polymorphism.